Brief: Adagene Announces Third Clinical Trial Collaboration With Merck
19/08/2021 12:18
Aug 19 (Reuters) - Adagene Inc 978y.F :
* ADAGENE ANNOUNCES THE THIRD CLINICAL TRIAL COLLABORATION
WITH
MERCK TO ADVANCE ANTI-CD137 AGONIST, ADG106, IN COMBINATION
THERAPY WITH KEYTRUDA® (PEMBROLIZUMAB)
* ADAGENE INC - AGREEMENT INCLUDES AN OPEN-LABEL, DOSE
ESCALATION
AND EXPANSION CLINICAL STUDY OF ADG106 IN COMBINATION WITH
MERCK'S ANTI-PD-1 KEYTRUDA
Source text for Eikon: ID:nGNX2rqv46
Further company coverage: 978y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate